Drugmakers to continue facing growing generic competition in 2013

17 February 2013

Last year saw the expiration of patents for several blockbuster drugs, leading to increasing generic competition. The trend is expected to continue in 2013, with patents on a number of blockbuster drugs set to expire. For drug manufacturers, intensifying generic competition is a major concern.

Meanwhile, companies such as Amarin (Nasdaq: AMRN) and Forest Laboratories (NYSE: FRX) are also assessing the impact of US President Barack Obama's Affordable Care Act (ACA). The financial web site StockCall has released free charting and technical research on these two companies.

Generic competition is a major concern for large pharmaceutical companies as well as biotechnology firms. Earlier this month, Merck & Co. had reported a 7% drop in its fourth quarter profit due to hits from generic competition (The Pharma Letter February 4).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK